Possibia

5569538

Last Update Posted: 2023-05-23

Recruiting

All Genders

accepted

18 Years +

40 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with myelofibrosis.

Eligibility

Relevant conditions:

Myelofibrosis

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

Harinder Gill, MD

gillhsh@hku.hk

+852 22554542

Data sourced from ClinicalTrials.gov